Table 3.
Top annotated GO, KEGG and IPA pathways in the SC of BAC-ATXN2-Q72 mice versus wild-type and −log10(P-value) for the indicated comparisons. Benjamini probabilities corrected for multiple pairwise comparisons were calculated for GO and KEGG terms (if significance was not achieved, uncorrected probabilities are shown, indicated by asterisks)
| GO | KEGG | IPA | |||
|---|---|---|---|---|---|
| TG versus WT (untreated) | |||||
| Glial cell development | 5.41 | Cholesterol metabolism | 3.16 | Hepatic fibrosis/hepatic stellate cell activation | 5.19 |
| Glial cell differentiation | 5.19 | Herpes simplex infection | 1.65 | Interferon signaling | 4.74 |
| Ensheathment of neurons | 4.57 | LXR/RXR activation | 4.68 | ||
| Axon ensheathment | 4.57 | Th2 pathway | 3.99 | ||
| Gliogenesis | 4.57 | Th1 and Th2 activation pathway | 3.88 | ||
| Fatty acid biosynthetic process | 4.57 | ||||
| TG-SAL versus WT-SAL | |||||
| Lipid metabolic process | 9.02 | Steroid biosynthesis | 2.07 | Superpathway of cholesterol biosynthesis | 9.19 |
| Fatty acid biosynthetic process | 5.97 | Fatty acid metabolism | 1.98 | Cholesterol biosynthesis I | 7.20 |
| Sterol biosynthetic process | 4.82 | Biosynthesis of unsaturated fatty acids | 1.89 | Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | 7.20 |
| Steroid metabolic process | 3.63 | Biosynthesis of antibiotics | 1.85 | Cholesterol biosynthesis III (via desmosterol) | 7.20 |
| Unsaturated fatty acid biosynthetic process | 2.65 | Hepatic fibrosis/hepatic stellate cell activation | 4.93 | ||
| Yellow module | |||||
| Ion transport | 4.29* | Biosynthesis of unsaturated fatty acids | 3.12* | Tryptophan degradation X (mammalian via tryptamine) | 3.75 |
| Fatty acid biosynthetic process | 3.94* | Nitrogen metabolism | 2.99* | Putrescine degradation III | 2.85 |
| Aging | 3.80* | Chemical carcinogenesis | 2.41* | Th2 pathway | 2.76 |
| Adult locomotory behavior | 3.42* | Neuroactive ligand–receptor interaction | 2.25* | Oleate biosynthesis II (animals) | 2.60 |
| Unsaturated fatty acid biosynthetic process | 3.33* | Metabolism of xenobiotics by cytochrome P450 | 2.08* | Hepatic fibrosis/hepatic stellate cell activation | 2.56 |
| Lightgreen module | |||||
| Sterol biosynthetic process | 5.39 | Steroid biosynthesis | 3.07 | Superpathway of cholesterol biosynthesis | 10.50 |
| Lipid metabolic process | 2.74 | Biosynthesis of antibiotics | 1.92 | Cholesterol biosynthesis I | 8.31 |
| Cholesterol biosynthetic process | 2.73 | Neuroactive ligand–receptor interaction | 1.80 | Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | 8.31 |
| Steroid metabolic process | 2.63 | Cholesterol biosynthesis III (via desmosterol) | 8.31 | ||
| Steroid biosynthetic process | 2.18 | Zymosterol biosynthesis | 4.46 | ||
| Midnightblue module | |||||
| Defense response to virus | 26.81 | Herpes simplex infection | 7.49 | Interferon signaling | 13.20 |
| Immune system process | 22.69 | Influenza A | 6.49 | Activation of IRF by cytosolic pattern recognition receptors | 12.40 |
| Innate immune response | 19.78 | Measles | 6.51 | Antigen presentation pathway | 7.63 |
| Response to virus | 17.48 | Hepatitis C | 5.47 | Role of RIG1-like receptors in antiviral innate immunity | 5.70 |
| Cellular response to interferon-beta | 17.16 | RIG-I-like receptor signaling pathway | 2.94 | Role of pattern recognition receptors in recognition of bacteria and viruses | 5.40 |